Press Releases

TORONTO, ONTARIO–(Marketwired – Feb. 25, 2014) – Arch Biopartners Inc (“Arch” or the “Company”) (CSE:ACH)(OTCBB:FOIFF) announced today it has raised $228,900 via a non-brokered private placement of 817,500 Units at a price of $0.28 per Unit.

Read more

TORONTO, ONTARIO–(Marketwired – Nov. 20, 2013) – Arch Biopartners Inc (Arch) or (the Company) (CNSX:ACH)(OTCBB:FOIFF) announced today that data relating to proprietary technology identifying brain tumor targeting peptides developed by Dr. Stephen Robbins, Dr.

Read more

TORONTO, ONARIO–(Marketwired – Sept. 17, 2013) – Arch Biopartners Inc (Arch) or (the Company) (CNSX:ACH)(OTCBB:FOIFF) announced today Dr. Patrick Smith and Dr. Craig Rayner of d3 Medicine have been appointed drug development advisors to the Company.

Read more

TORONTO, ONTARIO–(Marketwired – Sept. 12, 2013) – Arch Biopartners Inc (Arch) or (the Company) (CNSX:ACH)(OTCBB:FOIFF) announced today that the U.S. Patent and Trademark Office has issued US Patent 8,530,429 protecting its peptide technology which targets brain tumour initiating cells (BTICs) and invasive glioma cells (IGCs).

Read more

TORONTO, ONTARIO–(Marketwired – Aug. 14, 2013) – Arch Biopartners Inc (Arch) or (the Company)(CNSX:ACH) (OTCBB:FOIFF) announced today it has been accepted by the Consulate General of Canada, San Francisco/Silicon Valley to join the Life Sciences Canadian Technology Accelerator (CTA) at QB3 at the University of California San Francisco.

Read more

TORONTO, ONTARIO–(Marketwired – June 6, 2013) – Arch Biopartners Inc (Arch) or (the Company) (CNSX:ACH) (OTCBB:FOIFF) announced today that the U.S. Patent and Trademark Office has issued an additional patent for an invention preventing or inhibiting the growth of biofilm formation on surfaces.

Read more

TORONTO, ONTARIO–(Marketwired – April 22, 2013) – Arch Biopartners Inc (“Arch” or the “Company”)(CNSX:ACH)(OTCBB:FOIFF) today announced Dr. Stephen Robbins and his co-collaborators have been awarded $750,000 from Alberta Innovates’ Collaborative Research and Innovation Opportunities (“CRIO”) Cancer Project to support his team’s ongoing work in developing new diagnostic and therapeutic treatments for malignant brain tumours.

Read more

TORONTO, ONTARIO–(Marketwired – April 3, 2013) – Arch Biopartners Inc (“Arch” or the “Company”) (CNSX:ACH)(OTCBB:FOIFF) today announced that Arch scientists have co-authored a paper disclosing findings that links inflammatory bowel disease (“IBD”) to caspase 1, a key enzyme that regulates inflammation and cell homeostasis in the gut.

Read more

TORONTO, ONTARIO–(Marketwire – April 1, 2013) – Arch Biopartners Inc. (“Arch” or the “Company”) (CNSX:ACH)(OTCBB:FOIFF) today announced that the Company received approval from shareholders to approve all resolutions that were put forth at its Annual Meeting of Shareholders held on March 29, 2013 in Toronto (the “Meeting”) and as disclosed in its management information circular filed on SEDAR in connection to the Meeting.

Read more